Profound weight loss associated with reboxetine use in a 44-year-old woman.
We report a case of significant weight loss experienced by a 44-year-old Caucasian woman treated with reboxetine. She was treated with this drug at 12 mg daily for a total duration of 11 months. During the corresponding period her body mass index (BMI) decreased from a baseline of 21.4 kg m(-2) to a low of 16.8 kg m(-2). Withdrawal of the drug led to a full recovery of her BMI. The strongest evidence linking reboxetine to this woman's weight loss laid in the fact that the re-introduction of the drug subsequently caused a similar negative impact in her BMI.
Lu
T Y-T
TY
Department of Clinical Pharmacology & Centre for Neuroscience, Flinders Medical Centre and Flinders University, Adelaide, Australia.
Kupa
A
A
Easterbrook
G
G
Mangoni
A A
AA
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy; D015992:Body Mass Index; D005260:Female; D006801:Humans; D009025:Morpholines / Q000009:adverse effects*; D000077593:Reboxetine; D015431:Weight Loss / Q000187:drug effects*
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine